Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Haematologica|September 28, 2023
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II studyChristopher R Flowers, Matthew J Matasar, Alex F Herrera, et al.
Frontiers in Pharmacology|February 15, 2013
Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML PatientTorsten H Nielsen, Nathalie Johnson, Nicolas Garnier, et al.
Leukemia & Lymphoma|March 11, 2020
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemiaSarit Assouline, Lilian Amrein, Raquel Aloyz, et al.
Blood Advances|November 8, 2021
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort dataLaurie H Sehn, Mark Hertzberg, Stephen Opat, et al.
British Journal of Haematology|November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphomaMichelle Fanale, Sarit Assouline, John Kuruvilla, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialMatthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
Blood Neoplasia|June 8, 2026
A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18)Sarit Assouline, Anca Prica, Diego Villa, et al.
Blood Advances|May 13, 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORALSarit Assouline, Shen Li, Christian Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell LymphomaLaurie H Sehn, Alex F Herrera, Christopher R Flowers, et al.
American Journal of Hematology|June 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell LymphomaJulio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, et al.
Pageof 9